NASDAQ: OPTH

Branding A Psychedelic Medicine Maker.

Brand, website, investor presentation, packaging, events and market intelligence for Optimi Health.

20slides in the investor presentation
3product packs: MDMA 40 mg, MDMA 60 mg and psilocybin extract

Client: Optimi Health
Industry: Healthcare and pharma, Financial services and IR
Market: Canada
Engagement: Ongoing
Work: Investor relations, Websites, Branding

A Licensed Drug Maker In A Market That Is Just Opening.

Optimi Health makes GMP-compliant MDMA and psilocybin at Health Canada-licensed facilities in British Columbia, and its products already reach patients under Australia's Authorized Prescriber Scheme.

The brief: build credibility with investors in psychedelic medicine, sharpen the brand for clinics, pharmacies and investors, and give leadership institutional-grade market intelligence.

OPTH

listed on Nasdaq

medicines in market: MDMA and psilocybin

product packs designed by Dart

headquartered in Vancouver, British Columbia

Source: Optimi investor materials, 2026.

Six Workstreams, One Look.

A calm, clinical identity that reads as pharmaceutical first, carried across the brand system, the website, the investor presentation, the packs, the booth and the reporting.

Clinics, regulators and investors all meet the same company, whichever piece they pick up first.

01Brand systemBrand guideline, logo use, palette and print stationery.

optimihealth.ca pages laid out around a laptop

02WebsitePlanned, designed and built for clinics, pharmacies and investors.

Optimi investor presentation pages laid out

03Investor presentationA 20-slide deck for institutional and retail investors.

04Packaging and packshotsCapsule packs for MDMA and psilocybin, shot from three angles.

05EventsA conference booth and an exhibition stand in the brand.

Capsule production line at the GMP facility

06Market intelligenceA monthly report on sentiment, peers, insiders and press for leadership.

The Brand.

A calm, clinical identity that reads as pharmaceutical first, so clinics, regulators and investors take it seriously.

Psychedelic medicine is a new category with a reputation problem. The brand answers it with restraint: a simple mark, a teal palette, clean sans type and photography of the real facility.

Logo and logo use
Teal palette and type
Brand guideline
Stationery
GMP facility film

One System Across Every Touchpoint.

The mark, the teal palette and clean sans type, defined in the brand guideline and used the same way on the website, the deck and the packs.

On light.

Reversed on teal.

The Mark.
A simple symbol and wordmark that work at the size of a capsule label and the width of a booth wall.
The Palette.
Teal as the brand colour, with one colour per product on the packs so each is told apart at a glance.
The Type.
Clean sans type, set with room, so dosage and regulatory text stay legible.

The Real Facility, On Film.

The GMP-compliant facility in British Columbia, shown as it is, so the brand's credibility rests on the real thing.

GMP facility film.

The Website.

One site that speaks to three audiences: the clinics that prescribe, the pharmacies that dispense and the investors who fund.

Each audience finds its answer from the home page. The science is explained plainly, the products are listed for regulated clinical use, and the investor route is one click away.

Site planning and structure
Design in Figma
WordPress build
Google Analytics

Planned For The People Optimi Serves.

optimihealth.ca, as designed by Dart.

Three Audiences.
Clinics, pharmacies and investors each find their answer from the home page.
Clear On The Science.
What Optimi does, the products it supplies to clinics and its psilocybin products for regulated clinical use.
Built On WordPress.
Designed in Figma, built and tracked with Google Analytics.

The Investor Presentation.

A complex, regulated story told in 20 slides an investor can follow in one sitting.

Written and designed for institutional and retail investors in January 2026, from the corporate overview to unit economics, with the management team and the GMP facility as proof.

20 slides
Corporate overview and market
Products, distribution and the Australian model
Unit economics and peer valuation
Team, facility and close

20 Slides From Company To Unit Economics.

The order an investor needs: who Optimi is, why the market exists, what it sells, how it reaches patients, and what the numbers look like.

Corporate overview
The global burden of depression and PTSD
MDMA and psilocybin capsules and distribution
The Australian direct-to-clinic model
Special access programs, rescheduling and U.S. strategy
Exports, unit economics and patient opportunity
Peer valuation, management and the GMP facility

Investor presentation cover: The Direct-to-Clinic Pharmaceutical Drug Manufacturer — **Cover.** Investor presentation, January 2026.

Hard Numbers Made Easy To Read.

Six of the twenty. Each data slide carries one idea, one chart and the source.

Corporate overview slide — Corporate overview.

MDMA capsules and distribution slide — MDMA capsules and distribution.

Australian direct-to-clinic model slide — The direct-to-clinic model.

U.S. psychedelic landscape slide — U.S. landscape and strategy.

Targeted unit economics slide — Targeted unit economics.

Valuation and drug pipeline comparison slide — Valuation against peers.

Pages from the January 2026 investor presentation.

People, Proof And The Plant.

The management team, the GMP facility in photographs, and a close that asks for the meeting, with the tickers and the investor relations contact on the last page.

Experienced management team slide — **The team.** On one page.

GMP-compliant manufacturing facility slide — **The facility.** Shown in photographs.

Closing slide with investor relations contact — **The close.** Tickers and the IR contact, one email away.

Packs, Packshots And Events.

The product as a clinic, a pharmacist and a conference visitor sees it.

A colour per product, the molecule drawn on the label and the dose set large. Each product is rendered from three angles so the deck, the site and the press all have the right image.

MDMA 40 mg, MDMA 60 mg and psilocybin extract packs
Front, top-down and two-shot renders
Conference booth
Exhibition stand

Packaging A Clinic Can Trust On Sight.

One label system, three products. A colour per product, the molecule drawn on the label and the dose set large, so each is told apart at a glance.

Psilocybin extract from above — **Psilocybin extract.**

MDMA 40 mg two-bottle packshot — MDMA 40 mg, two-bottle shot.

Psilocybin extract two-bottle packshot — Psilocybin extract, two-bottle shot.

MDMA 60 mg two-bottle packshot — MDMA 60 mg, two-bottle shot.

Packs and renders by Dart.

Ready For The Conference Floor.

A conference booth and an exhibition stand, designed in the brand: back wall, counter, product display, roll-up banner and promo counter.

The Product At Eye Level.
The packs sit on the counter and on the wall, so the first thing a visitor sees is the thing Optimi makes.
One Line Across Every Surface.
The direct-to-clinic drug manufacturer, on the booth, the stand and the banner.

Optimi exhibition stand with roll-up banner and promo counter — **Exhibition stand.** Roll-up banner and promo counter.

Booth and stand designs by Dart.

Market Intelligence.

A custom report that puts the stock, the peers, the insiders and the press on one page for leadership.

The view an institutional desk would give, made for a company at Optimi's stage. Five modules, delivered on an ongoing basis, so the board reads the market the way the market reads Optimi.

Media and price
Sentiment
Competitors
Insiders
Press

Five Modules, One Report.

Built for a small-cap board. Each module answers one question leadership asks every month.

Media and price.
The share price over the year, with every financing, launch and milestone marked on the line.
Sentiment.
One score with the bullish, neutral and bearish split behind it, plus momentum, news cadence and social volume.
Competitors.
Optimi beside its listed peers: market cap, stage and latest event.
Insiders.
Holdings and recent buying by the CEO and the chairman.
Press.
The latest releases, tagged by type: listing, milestone, treatment, export, production.

What Optimi Took To Market.

One brand system across the website, the investor presentation, the packs and the booth, ready for clinics, pharmacies and capital markets.

slides in the investor presentation

product packs: MDMA 40 mg, MDMA 60 mg and psilocybin extract

packshot angles for every product

modules in the market intelligence report

Counts of the deliverables shown in this case study.

What We Delivered.

The work on this page, by service. Each card opens the full service page.

Optimi Health investor presentation cover slide

Investor relations marketingInvestor presentationsIR website designStock sentiment trackingExplore the service

Brand and designPackaging designBrand guidelinesExplore the service

Questions About Our Work With Optimi Health.

Still curious? Book a call or email info@dartmarketing.ai.

What Did Dart Deliver For Optimi Health?

A full website build, a brand guide and stationery, a 20-slide investor presentation for institutional and retail audiences, packaging and packshots for three products, a conference booth and exhibition stand, and an ongoing market intelligence report.

Where Is Optimi Health Listed?

On Nasdaq under the ticker OPTH.

What Does Optimi Health Make?

MDMA and psilocybin drug products for regulated medical use, made at Health Canada-licensed facilities in British Columbia and supplied directly to authorized clinics and pharmacies.